Sartorius AG ADR (SOAGY)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 2,336 | 3,449 | 4,175 | 3,396 | 3,381 | 3,398 | 3,586 | 3,723 |
| Operating profit | €m | 626 | 620 | ||||||
| Net profit | €m | 210 | 319 | 678 | 205 | 84 | 149 | 197 | - |
| EPS reported | € | 0.43 | 0.57 | ||||||
| Operating cashflow per share | € | 1.83 | 2.05 | ||||||
| Capex per share | € | 1.23 | 1.28 | ||||||
| FCF per share | € | 0.60 | 0.77 | ||||||
| Free cash flow | €m | 206 | 306 | ||||||
| Net debt | €m | 3,524 | 3,547 | ||||||
| Book value equity | €m | 2,706 | 2,823 | ||||||
| Book value per share | € | 7.84 | 8.14 | ||||||
| Number of shares | m | 345.23 | 346.84 | ||||||
| DPS (TTM paid) | € | 0.15 | 0.15 |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 114.99 | 105.52 | ||||||
| P/B LTM | x | 6.31 | 6.05 | ||||||
| P/S LTM | x | 5.02 | 4.76 | ||||||
| P/FCF LTM | x | 82.98 | 55.71 | ||||||
| EV/EBITDA LTM | x | 20.22 | 19.89 | ||||||
| EV/Sales LTM | x | 6.12 | 5.34 | ||||||
| Earnings Yield LTM | % | +0.87% | +0.95% | ||||||
| FCF Yield | % | +1.21% | +1.79% | ||||||
| Quality | |||||||||
| ROE | % | +5.50% | +6.05% | ||||||
| ROIC | % | +4.93% | +4.61% | ||||||
| Operating margin | % | +18.41% | +16.52% | ||||||
| Gross margin | % | +46.26% | +45.59% | ||||||
| FCF/Sales | % | +6.05% | +7.48% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +79.17% | +137.50% | ||||||
| Sales Growth YoY | % | +0.53% | +6.07% | ||||||
| Net Income Growth YoY | % | +77.13% | +134.10% | ||||||
| FCF Growth | % | -63.69% | -45.91% | ||||||
| Operating Profit Growth | % | +43.11% | +41.85% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +0.29% | +0.33% | ||||||
| Dividend Growth | % | +0.70% | +0.70% | ||||||
| Payout Ratio | % | +32.81% | +62.59% | ||||||
| FCF/Debt | x | 0.05 | 0.08 | ||||||
| Net Debt/EBITDA | x | 3.64 | 3.74 | ||||||
| EBIT/Net interest | x | 3.29 | 2.44 | ||||||
| Net debt/market cap | % | +23.88% | +26.86% | ||||||
| Net debt/Equity | x | 1.30 | 1.26 | ||||||
| Gross debt/equity | x | 1.58 | 1.44 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Sartorius AG engages in the provision of solutions for biopharmaceutical research. It operates through following divisions: Bioprocess Solutions (BPS), and Lab Products and Service (LPS). The Bioprocess Solutions division focuses on single-use solutions, helps customers manufacture biotech medications and vaccines safely and efficiently. The Lab Products and services division serves the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The company was founded by Florence Sartorius, Sr. in 1870 and is headquartered in Goettingen, Germany.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Sartorius AG engages in the provision of solutions for biopharmaceutical research. It operates through following divisions: Bioprocess Solutions (BPS), and Lab Products and Service (LPS). The Bioprocess Solutions division focuses on single-use solutions, helps customers manufacture biotech medications and vaccines safely and efficiently. The Lab Products and services division serves the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The company was founded by Florence Sartorius, Sr. in 1870 and is headquartered in Goettingen, Germany.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free